{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:12:24Z","timestamp":1760145144269,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T00:00:00Z","timestamp":1535500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.repc.2017.10.013","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T07:33:10Z","timestamp":1548401590000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novas perspetivas para a abordagem dos efeitos cardiovasculares dos inibidores da tirosinacinase em doentes com leucemia mieloide cr\u00f3nica"],"prefix":"10.1016","volume":"38","author":[{"given":"Ana G.","family":"Almeida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ant\u00f3nio","family":"Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lurdes","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu\u00eds","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patr\u00edcia","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Mota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Fontes\u2010Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.repc.2017.10.013_bib0125","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five\u2010year follow\u2010up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2017.10.013_bib0130","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/leu.2015.36","article-title":"Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML\u2010study IV","volume":"29","author":"Kalmanti","year":"2015","journal-title":"Leukemia."},{"key":"10.1016\/j.repc.2017.10.013_bib0135","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic\u2010phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2017.10.013_bib0140","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2014-09-594432","article-title":"Vascular safety issues in CML patients treated with BCR\/ABL1 kinase inhibitors","volume":"125","author":"Valent","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.repc.2017.10.013_bib0145","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia."},{"key":"10.1016\/j.repc.2017.10.013_bib0150","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.blre.2014.06.001","article-title":"Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia","volume":"28","author":"Mathisen","year":"2014","journal-title":"Blood reviews."},{"key":"10.1016\/j.repc.2017.10.013_bib9155","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kertel\u00e3","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.repc.2017.10.013_bib9593","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood-2007-01-070144","article-title":"Congestive heart failure is a rare event in patients receiving imatinib therapy","volume":"110","author":"Atallah","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.repc.2017.10.013_bib0155","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.2010.030494","article-title":"Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100mg or 50mg daily","volume":"96","author":"Krauth","year":"2011","journal-title":"Haematologica."},{"key":"10.1016\/j.repc.2017.10.013_bib0160","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or high\u2010dose imatinib for chronic\u2010phase chronic myeloid leukemia after failure of first\u2010line imatinib: a randomized phase 2 trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.repc.2017.10.013_bib0165","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1038\/bmt.2008.415","article-title":"Reversible dasatinib\u2010induced pulmonary arterial hypertension and right ventricle failure in a previously allografted CML patient","volume":"43","author":"Mattei","year":"2009","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.repc.2017.10.013_bib0170","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s40264-013-0050-x","article-title":"Tyrosine kinase inhibitors: their on\u2010target toxicities as potential indicators of efficacy","volume":"36","author":"Shah","year":"2013","journal-title":"Drug Safety."},{"key":"10.1016\/j.repc.2017.10.013_bib0175","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med."},{"key":"10.1016\/j.repc.2017.10.013_bib9595","first-page":"3134","article-title":"Increased Risk of Cardiovascular Events Associated with TKI Treatment in Chronic Phase Chronic Myeloid Leukemia","volume":"124","author":"Dahl\u00e9n","year":"2014","journal-title":"Data from Swedish Population-Based Registries Blood"},{"key":"10.1016\/j.repc.2017.10.013_bib0180","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jnci\/djr292","article-title":"Severe peripheral arterial disease during nilotinib therapy","volume":"103","author":"Le Coutre","year":"2011","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.repc.2017.10.013_bib0185","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non\u2010tyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia."},{"key":"10.1016\/j.repc.2017.10.013_bib0190","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia."},{"key":"10.1016\/j.repc.2017.10.013_bib0195","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00277-014-2231-9","article-title":"Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment","volume":"94","author":"Breccia","year":"2015","journal-title":"Ann Hematol."},{"key":"10.1016\/j.repc.2017.10.013_bib0200","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J."},{"key":"10.1016\/j.repc.2017.10.013_bib0205","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3324\/haematol.2011.058776","article-title":"Clinical cardiac safety profile of nilotinib","volume":"97","author":"Kim","year":"2012","journal-title":"Haematologica."},{"key":"10.1016\/j.repc.2017.10.013_bib0210","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/ajh.24360","article-title":"Long\u2010term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome\u2010positive leukemias treated with bosutinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am J Hematol."},{"key":"10.1016\/j.repc.2017.10.013_bib0215","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1002\/ajh.24536","article-title":"Long\u2010term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and\/or nilotinib","volume":"91","author":"Cortes","year":"2016","journal-title":"Am J Hematol."},{"key":"10.1016\/j.repc.2017.10.013_bib0220","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI\u2010606) in chronic phase Philadelphia chromosome\u2013positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.repc.2017.10.013_bib0225","doi-asserted-by":"crossref","first-page":"e376","DOI":"10.1016\/S2352-3026(15)00127-1","article-title":"Ponatinib as first\u2010line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study","volume":"2","author":"Jain","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.repc.2017.10.013_bib0230","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association Between BCR\u2010ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events Major Molecular Response, and Overall Survival: A Systematic Review and Meta\u2010analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.repc.2017.10.013_bib0235","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2165\/11587800-000000000-00000","article-title":"interval prolongation and its associated risks with antipsychotics","volume":"25","author":"Nielsen","year":"2011","journal-title":"CNS drugs."},{"key":"10.1016\/j.repc.2017.10.013_bib0240","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1592\/phco.30.7.684","article-title":"Drug\u2010induced QT\u2010interval prolongation: considerations for clinicians","volume":"30","author":"Li","year":"2010","journal-title":"Pharmacotherapy."}],"container-title":["Revista Portuguesa de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255117307047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255117307047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:07:02Z","timestamp":1760108822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0870255117307047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0870255117307047"],"URL":"https:\/\/doi.org\/10.1016\/j.repc.2017.10.013","relation":{},"ISSN":["0870-2551"],"issn-type":[{"type":"print","value":"0870-2551"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novas perspetivas para a abordagem dos efeitos cardiovasculares dos inibidores da tirosinacinase em doentes com leucemia mieloide cr\u00f3nica","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2017.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}